PMID- 1845940
OWN - NLM
STAT- MEDLINE
DCOM- 19910212
LR  - 20190619
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 67
IP  - 2
DP  - 1991 Jan 15
TI  - Late effects of treatment for Wilms' tumor. A report from the National Wilms' 
      Tumor Study Group.
PG  - 331-6
AB  - The National Wilms' Tumor Study (NWTS) was initiated in 1969. One of its 
      objectives was to modulate treatments according to risk factors to minimize the 
      number and severity of treatment-related short-term and long-term iatrogenic 
      complications. The NWTS has therefore incorporated a Long Term Follow-up Study 
      (LTFS) within its framework to monitor late effects. The LTFS is confined to 
      relapse-free survivors alive 5 years or longer after initial surgery, and data 
      are collected using specifically designed forms. A total of 787 patients 
      registered on NWTS-1 or NWTS-2 (1969 to 1979) were eligible, of whom 680 (86%) 
      were available for analysis regarding musculoskeletal, cardiovascular, and 
      neuropsychologic status, and the presence of benign and malignant tumors. 
      Patients with early-stage disease who were treated with radiation had scoliosis 
      reported, along with other musculoskeletal abnormalities (32 versus 2), nearly 
      seven times as often as did the members of the cohort population who did not 
      undergo radiation (35 of 57 versus 5 of 53, respectively). The difference in 
      cardiovascular problems recorded in survivors who did and did not receive 
      Adriamycin (Adria Laboratories, Columbus, OH) (2.4 versus 1.1 per 100-person 
      years at risk) had borderline statistical significance (P = 0.06). No excess in 
      neuropsychologic events was reported for those given the neurotoxin vincristine. 
      When considering patients with disease of all stages, all 5 second malignant 
      tumors occurred in the 623 patients who underwent radiation (RT patients); benign 
      tumors were also more frequent in RT patients than in those patients who did not 
      undergo radiation (41 of 486 or 8% versus 4 of 194 or 2%). Continuing study of 
      this unique body of patients is needed, especially for those given Adriamycin, 
      because of the known long interval needed for latent cardiomyopathy to become 
      clinically manifest in some patients.
FAU - Evans, A E
AU  - Evans AE
AD  - Children's Cancer Research Center, Children's Hospital of Philadelphia, 
      Pennsylvania 19104.
FAU - Norkool, P
AU  - Norkool P
FAU - Evans, I
AU  - Evans I
FAU - Breslow, N
AU  - Breslow N
FAU - D'Angio, G J
AU  - D'Angio GJ
LA  - eng
GR  - CA-42326/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 80168379AG (Doxorubicin)
SB  - IM
MH  - Cardiovascular Diseases/chemically induced
MH  - Child
MH  - Combined Modality Therapy
MH  - Doxorubicin/adverse effects
MH  - Follow-Up Studies
MH  - Humans
MH  - Mental Disorders/epidemiology
MH  - Neoplasms, Radiation-Induced/epidemiology
MH  - Prevalence
MH  - Radiation Injuries/epidemiology
MH  - Radiotherapy/*adverse effects
MH  - Risk Factors
MH  - Scoliosis/chemically induced/epidemiology
MH  - Time Factors
MH  - Wilms Tumor/*therapy
EDAT- 1991/01/15 00:00
MHDA- 1991/01/15 00:01
CRDT- 1991/01/15 00:00
PHST- 1991/01/15 00:00 [pubmed]
PHST- 1991/01/15 00:01 [medline]
PHST- 1991/01/15 00:00 [entrez]
AID - 10.1002/1097-0142(19910115)67:2<331::aid-cncr2820670202>3.0.co;2-7 [doi]
PST - ppublish
SO  - Cancer. 1991 Jan 15;67(2):331-6. doi: 
      10.1002/1097-0142(19910115)67:2<331::aid-cncr2820670202>3.0.co;2-7.